Lueprasitsakul W, Abend S, Alex S, Reinhardt W, Appel M C, Braverman L E
Division of Endocrinology and Metabolism, University of Massachusetts Medical School, Worcester.
Acta Endocrinol (Copenh). 1990 Jul;123(1):79-83. doi: 10.1530/acta.0.1230079.
Thalidomide, a derivative of glutamic acid, has immunosuppressive effects and suppresses graft-vs-host disease in the rat and following bone marrow transplantation in man. It is effectively used in the treatment of erythema nodosum leprosum and has a potential therapeutic effect in a variety of autoimmune diseases. In view of these observations, we evaluated the effect of thalidomide on the incidence of spontaneous and iodine-induced lymphocytic thyroiditis and spontaneous insulin dependent diabetes mellitus in the BB/Wor rat. Thalidomide did not suppress the incidence of lymphocytic thyroiditis and serum anti-thyroglobulin antibodies or affect the serum concentrations of T4, T3 and TSH in this rat model. Thalidomide also did not affect the incidence of insulin dependent diabetes mellitus. In contrast to preliminary studies in man and rat demonstrating efficacy in the therapy of autoimmune diseases, thalidomide did not prevent or suppress autoimmune lymphocytic thyroiditis or insulin-dependent diabetes mellitus in the BB/Wor rat.
沙利度胺是谷氨酸的衍生物,具有免疫抑制作用,可抑制大鼠的移植物抗宿主病以及人类骨髓移植后的该病。它被有效地用于治疗麻风结节性红斑,并且在多种自身免疫性疾病中具有潜在的治疗作用。鉴于这些观察结果,我们评估了沙利度胺对BB/Wor大鼠自发性和碘诱导的淋巴细胞性甲状腺炎以及自发性胰岛素依赖型糖尿病发病率的影响。在该大鼠模型中,沙利度胺并未抑制淋巴细胞性甲状腺炎的发病率和血清抗甲状腺球蛋白抗体,也未影响血清T4、T3和促甲状腺激素的浓度。沙利度胺也未影响胰岛素依赖型糖尿病的发病率。与在人和大鼠中显示对自身免疫性疾病治疗有效的初步研究相反,沙利度胺并未预防或抑制BB/Wor大鼠的自身免疫性淋巴细胞性甲状腺炎或胰岛素依赖型糖尿病。